Cell & Gene Therapy CMC Dossier Architect

CMC regulatory writers and technical directors at CGT companies preparing IND or BLA submissions need to structure the Chemistry, Manufacturing, and Controls section to meet FDA Office of Tissues and Advanced Therapies (OTAT) expectations, which differ substantially from small molecule or conventional biologic standards.